Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial

BACKGROUND: The treatment of acute promyelocytic leukemia (APL) has been revolutionized in the past two decades by the advent of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). It suggests that non-high-risk APL patients can be cured without chemotherapy. However, ATRA plus chemotherapy i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xinxin, Zhang, Huiyun, Chen, Limei, Wang, Mengchang, Xi, Jieying, Liu, Xin, Xie, Ming, Li, Dengzhe, Gulati, Ekamjyot Singh, Gong, Sha, Wang, Huaiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126003/
https://www.ncbi.nlm.nih.gov/pubmed/30185214
http://dx.doi.org/10.1186/s13063-018-2812-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126003/
https://www.ncbi.nlm.nih.gov/pubmed/30185214
http://dx.doi.org/10.1186/s13063-018-2812-3

Ejemplares similares